Skip to main content

Vogenx, Inc.

corporate_fare Company Profile

Vogenx, Inc.

VOGX·NASDAQ·Life Sciences·CIK 0001903784

Vogenx, Inc. is a clinical-stage drug development company focused on creating treatments for metabolic conditions, specifically post-bariatric hypoglycemia (PBH) and gastroparesis. The company's product pipeline includes drug candidates such as Mizagliflozin and VGX-2857. Additionally, Vogenx, Inc. is developing VGX-001, which is a human monoclonal antibody intended for the treatment of type 1 diabetes (T1D). The company's operations are based in Raleigh, North Carolina, where it was incorporated in 2021. Vogenx, Inc. serves healthcare providers, physicians, and third-party payors within the United States market.

Vogenx, Inc. (NASDAQ:VOGX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 3 items for VOGX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-06, rated 7/10. Across its 3 most recent items scored 7 or higher, the top rating is 8/10, with 2 rated 8 or above. Recent SEC coverage for VOGX spans 10-Q, 424B4.

Recent high-impact activity:

  • Vogenx Posts $4.9M Q3 Loss, But $3.4M Warrant Charge Skews the Number
  • Vogenx's First 10-Q Flags Material Weaknesses and Restatement
  • Vogenx Prices $81.25M IPO at $13.00/Share, Lists on Nasdaq

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 74,122 shares in VOGX as of the October 30, 2026 settlement, a 93.6% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 22.6% of VOGX volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)74,122 shares as of October 30, 2026
Change vs prior period▲ 93.6%
Days to cover1.00 at avg daily volume of 80,725
Daily short volume (FINRA facilities)22.6% of 58,599 shares on November 20, 2026
5-day average short volume51.8%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for VOGX, detected from its recent SEC filings · based on capital-structure filings through 2026-08-19.

1 recent capital raise

IPO Priced at $13.00/Share · Net Proceeds to Fund Clinical Trials

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with V →
$11.87
52-week range · as of 2026-09-17 $11.87 – $36
Market cap
$176.33M
Volume
100.9K (0.9× avg)
3-mo avg 107.1K
Live data · 2026-11-22 07:27 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed VOGX - Latest Insights

VOGX
Nov 06, 2026, 6:30 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $17.51
Real-time Price: $11.87 info
Change: -$5.64 (-32%) info
Market Cap: $176.33M info
VOGX
Sep 17, 2026, 4:24 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $34.13
Real-time Price: $11.87 info
Change: -$22.26 (-65%) info
Market Cap: $176.33M info
VOGX
Aug 12, 2026, 4:24 PM EDT
Filing Type: 424B4
Importance Score:
8
Price at Filing: $12.69
Real-time Price: $11.87 info
Change: -$0.820 (-6%) info
Market Cap: $176.33M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets